New startup ideas · Health and bio · Healthcare and bio
startup idea
Titerworks
A shared process model for biologics manufacturing, trained on runs nobody publishes.
Titerworks runs its own farm of several hundred parallel micro-bioreactors and analytics robots, and uses it to train models that predict titer, aggregation and impurity profiles for a new molecule before a pharma company books a pilot suite.
- Software subscription
- Enterprise
- $100B+ market
- Network effects, winner takes most
- Global from day one
4/5
venture judge
47
similar startups, last 2 years (117 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$2,300 · 6 weeks · 20 prospects
For under $2,500 and six weeks, prove that US CDMO process development directors will sign CDAs to share bispecific run data and pay $4,500 up front for predictions, before any robot is bought.
1Focus group: who and where
Director or VP of Process Development at a US CDMO with 200-2,000 employees running mammalian cell culture programs, who ate the cost of at least one failed or repeated bispecific antibody pilot campaign in the last 12 months
where to find 20 · LinkedIn Sales Navigator filtered to titles Director/VP Process Development or Upstream Process Development at US contract development and manufacturing organizations, plus badge scanning and pre-booked meetings at the BioProcess International Conference in Boston in September 2026
2Sell first, build later
A design-partner pilot: transfer runs for one retired molecule under CDA, receive a blind-benchmark scorecard plus a process risk report on one upcoming bispecific program within 45 days of data transfer, and hold a reserved capacity slot in the first robot-farm cohort in Q1 2027
the ask · $4,500 per pilot invoiced up front, with a stated year-one subscription of $60,000 per program if predictions beat their internal baseline
a real yes · A real yes is a paid invoice or a countersigned order form with a data-transfer date on it; conference enthusiasm, 'send us more info', and unpaid data-sharing offers with no signature are not
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Twenty failed-campaign interviews
$200 · 14 days
Founder books 20 thirty-minute calls via Sales Navigator outreach and BPI meeting requests. Script asks for the last pilot campaign that missed titer or purity spec, what the re-run cost, and whether any model would have flagged it. Log dollar cost per failure and who signs off on external data sharing.
keep going if · 12 of 20 name a specific campaign failure in the last 12 months costing over $250,000, and at least 8 say the blocker to sharing run data is terms, not policy
2. Blind benchmark data-transfer test
$600 · 21 days
Email each interviewed prospect a one-page offer: send historical runs for one retired bispecific molecule under a mutual CDA, and Titerworks returns predicted versus actual titer and aggregation within 30 days. This directly tests the stated risk that data never leaves their four walls, before spending anything on hardware. Use a two-way CDA template reviewed once by a life-sciences attorney.
keep going if · 4 of 15 offers result in a signed CDA and an actual data transfer within 21 days
3. Pre-sold design-partner pilot
$300 · 28 days
Pitch a paid pilot to every prospect who signed a CDA or confirmed a costly failure: a process risk report on their next bispecific cell line and media program, delivered in 45 days, produced by hand from their transferred data plus literature models, invoiced before work starts. No robot farm exists yet and the offer says so; they are buying first-cohort status.
keep going if · 3 prospects pay the $4,500 invoice, not just verbally agree
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$4,500
per prospect, refundable
how · Paid design-partner pilot invoiced up front through Stripe Invoicing, order form signed by the VP of Process Development; the invoice is roughly 5-7% of the year-one program subscription set up: Stripe Invoicing ↗
what it reserves · One of three first-cohort slots, priority scheduling on the future robot farm, and a locked $60,000 year-one program price
refund · Fully refunded if the benchmark and risk report are not delivered within 45 days of their data arriving
target · 3 paid pilots from 20 conversations within 42 days
Go: build it if
3 pilots paid ($13,500 collected), 4 signed CDAs with real run data transferred, and interview evidence that a prevented failed campaign is worth over $250,000 per program
Kill: stop if
After 25 conversations, fewer than 2 organizations will let any historical run data leave under CDA, or 0 paid pilots; that confirms the stated risk and the shared-model flywheel cannot start
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
67
Idea Score, 0-100 · raw 40.8 x 1.64
Crowded
competition: more crowded than 98% of ideas · headwind x0.51
+5.0
government priorities, secondary (561 matching grants)
Trend
62
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)68
- Rounds announced 2025+ in the sector55
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
68
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain50
- Founders' yes-rate in decks91
100x potential
81
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge75
- Market size axis100
- Moat axis100
- Neighbours still alive38
- Technologist judge100
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were shared, process, model, biologics, manufacturing, trained, nobody, farm.
The idea in full
- What
- Titerworks runs its own farm of several hundred parallel micro-bioreactors and analytics robots, and uses it to train models that predict titer, aggregation and impurity profiles for a new molecule before a pharma company books a pilot suite. Enterprise process development groups at pharma companies and CDMOs subscribe per program and get run designs, media and feed recommendations, and failure predictions; every run they execute, successful or not, is returned to the shared model. It sells to research and process development, before GMP, so nothing needs clearance to ship.
- Why now
- The radar shows the manufacturing and protein layer being funded right now rather than the target layer: AbInitio Bio (yc X26) is building 'The Intelligence layer for Drug Manufacturing', 10x Science (yc W26) is doing next-generation protein characterization, and Ambrosia Biosciences took a $100M Series B on 2026-03-31, which is the size of check that pays for wet lab capacity instead of just software.
- Wedge: first customer and entry point
- Start with one modality, bispecific antibody cell line and media optimization, sold founder to founder to three mid-size CDMOs who lose money on failed pilot campaigns and will trade run data for free capacity on the robot farm.
- Path to 100x
- Biologics manufacturing is a $100B+ spend line and roughly a third of pilot campaigns are re-run; a model that removes one failed campaign per program is worth seven figures a year per program. The mechanism is a data flywheel across competitors who cannot each build a robot farm: every added CDMO makes the predictions better for the next one, and process data is the one asset that does not exist in public literature, so the first company to aggregate it is the only one with it.
- Ceiling
- If each molecule class turns out to be idiosyncratic enough that data does not transfer, the company degrades into a specialised contract lab with revenue tied to robot hours.
- Closest real companies, as the generator saw them
- AbInitio Bio sits in the same layer but as software over a customer's existing plant data; Titerworks generates its own data on owned hardware, so it has predictions on day one for molecules a customer has never run. 10x Science and Scala Biodesign work on the molecule, not on how it is made at scale.
- Main risk
- Pharma process groups refuse to let run data leave their four walls, and the shared model never gets past the founder's own robots.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
4/5
Process run data exists nowhere public, so the first robot farm aggregating it across CDMOs owns a compounding asset in a $100B+ spend line.
Bootstrapper
1/5
Several hundred parallel micro-bioreactors and analytics robots is a nine-figure buildout before any pharma subscription.
Operator
3/5
A re-run pilot campaign costs seven figures and process groups feel it, but the flywheel needs competing CDMOs to share run data first.
Technologist
5/5
Several hundred owned micro-bioreactors generating process data absent from all public literature is a moat that deepens with every CDMO run returned.
Risk
4/5
Owns its micro-bioreactor farm so predictions exist without customer data, sells pre-GMP where nothing needs clearance, and spreads across multiple CDMOs.
trends
2/5
Why-now is Ambrosia's $100M round and adjacent startups existing, but a biologics data flywheel on owned robots was equally buildable in 2023.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (shared, process, model, biologics, manufacturing, trained, nobody, farm): 117 all-time, 47 from the last two years. Same matching as Idea Check.
The autonomous ERP for every manufacturer
CV and robotics to automate quality inspection in fish farms
Infrastructure for AI labs to focus on research.
Unsupervised Biological AI
Reimagining Hardware Design with multimodal AI
Unlock the Speed & Accuracy of Next-Gen Quality Testing
Reprogramming immunomodulation using AI to cure cancer
Calejo is an intelligence platforms that leverages the AI-potential helping corporates to optimize their business.
Internal industrial company data for frontier labs
Real-world data network for robots & world models
Agentic data layer for manufacturing & process industries.
Extrapolative AI to unlock First-in-Class drugs
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1135
startup-relevant grants in Healthcare and bio
$598M
awarded in the sector, tracked
130
opportunities open now in the sector
- CAREER: Multimodal Generative AI for Autonomous Biomolecular Design and Accelerated Discoveryawardhigh relevance
National Science Foundation · Info Integration & Informatics · $758K · posted 2026-05-25
- Implantable Intelligent Engineered System to Enable Virtual Bidirectional Muscle-Prosthesis Mechanical Interaction for Amputeesawardhigh relevance
National Science Foundation · M3X - Mind, Machine, and Motor, Special Initiatives, Dynamics, Control and System D · $809K · posted 2026-08-21
- I-Corps: Translation Potential of a marine-adapted radio frequency identification (RFID) and analytics platform for digital inventory management in shellfish aquacultureawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-19
- GOALI: Machine Learning Enabled Multiscale Modeling Platform and Virtual Sensing Digital Twin for Fatigue in Metals Additive Manufacturing (MAM)awardhigh relevance
National Science Foundation · Special Initiatives, Mechanics of Materials and Str, AM-Advanced Manufacturing · $900K · posted 2026-08-18
National Science Foundation · STTR Fast-Track · $305K · posted 2026-07-10
National Science Foundation · STTR Phase I · $305K · posted 2026-07-06
- Primate epigenetic and senescence biomarkers to advance aging science and anti-aging strategies.awardhigh relevance
NIH / NIA · SBIR phase I · $292K · posted 2025-09-20
NIH / NCI · SBIR phase I · $400K · posted 2025-09-18
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 119 → 224 → 170 → 92 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 24 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 38 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Software subscription
- Path to 100x
- Network effects, winner takes most
- Market size
- $100B+ market
- Capital intensity
- Capital-heavy (hardware, bio, infra)
- Speed to revenue
- R&D first, revenue after 3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Founder-led sales
- Moat
- Data moat
- Geography
- Global from day one
- Regulation
- Unregulated
- Vibe
- Boring business
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.